Journal of Diabetes & Clinical Practice
Open Access
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 284
Journal of Diabetes & Clinical Practice received 284 citations as per Google Scholar report
Journal of Diabetes & Clinical Practice peer review process verified at publons
Indexed In
- Google Scholar
- Publons
- ICMJE
Useful Links
Recommended Journals
Share This Page
Journal of Diabetes & Clinical Practice : Citations & Metrics Report
Articles published in Journal of Diabetes & Clinical Practice have been cited by esteemed scholars and scientists all around the world. Journal of Diabetes & Clinical Practice has got h-index 4, which means every article in Journal of Diabetes & Clinical Practice has got 4 average citations.
Following are the list of articles that have cited the articles published in Journal of Diabetes & Clinical Practice.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Total published articles |
55 | 31 | 31 | 37 | 12 | 8 | 1 | 0 |
Conference proceedings |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
11 | 24 | 23 | 28 | 16 | 13 | 14 | 20 |
| Journal total citations count | 284 |
| Journal impact factor | 0.75 |
| Journal 5 years impact factor | 0.86 |
| Journal cite score | 0.81 |
| Journal h-index | 4 |
| Journal h-index since 2019 | 4 |
 |
Lee, H., Park, S. E., & Kim, E. Y. (2021). Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of clinical medicine, 10(18), 4078. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Jiang, L. L., Zhang, P., Liu, B. L., Yan, R. N., Ye, L., Ma, J. H., & Li, F. F. (2021). Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial. BioMed Research International, 2021. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020). Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC medicine, 18(1), 1-23. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Ceriello, A., Ofstad, A. P., Zwiener, I., Kaspers, S., George, J., & Nicolucci, A. (2020). Long-Term HbA1c Variability and Cardiovascular Death: Insights from the EMPA-REG OUTCOME Trial. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Li, F. F., Liu, B. L., Yin, G. P., Yan, R. N., Zhang, D. F., Wu, J. D., ... & Ma, J. H. (2018). Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes. Scientific reports, 8(1), 1-7. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Stelmaszyk, A., Weso?owska, A., Pomieczy?ska, K., Iskakova, S., Frydrychowicz, M., Dworacki, G., & Dworacka, M. (2018). The impact of dapagliflozin on glucose excursions related to early proatherogenic derangement in the aortic wall. Saudi pharmaceutical journal, 26(8), 1192-1198. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Unnikrishnan, A. G., Saboo, B., Joshi, S., Kesavadev, J., Makkar, B. M., Agarwal, S., ... & Tiwaskar, M. (2019). Consensus Statement on Use of Ambulatory Glucose Profile in Patients with Type 2 Diabetes Mellitus Receiving Oral Antidiabetic Drugs. The Journal of the Association of Physicians of India, 67(11), 76-83. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Milonas, D., & Tziomalos, K. (2018). Sodium-glucose cotransporter 2 inhibitors and ischemic stroke. Cardiovascular & Haematological Disorders-Drug Targets (Formerly Current Drug Targets-Cardiovascular & Hematological Disorders), 18(2), 134-138. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Verbovoy, A. F., Pashentseva, A. V., Verbovaya, N. I., Madyanov, I. V., Sharonova, L. A., & Galkin, R. A. (2018). Modern approaches to management of cardiovascular risk factors at patients with diabetes mellitus type 2. Terapevticheskii arkhiv, 90(8), 113-117. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Ceriello, A., Ofstad, A. P., Zwiener, I., Kaspers, S., George, J., & Nicolucci, A. (2020). Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovascular diabetology, 19(1), 1-7. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Handelsman, Y. (2019). Rationale for the early use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Advances in therapy, 36(10), 2567-2586. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Araki, E., Watada, H., Uchigata, Y., Tomonaga, O., Fujii, H., Ohashi, H., ... & Langkilde, A. M. (2020). Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT?5): 52?week results from a randomized, open?label, phase III clinical trial. Diabetes, Obesity and Metabolism, 22(4), 540-548. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Papakitsou, I., Vougiouklakis, G., Elisaf, M. S., & Filippatos, T. D. (2019). Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clinical pharmacology: advances and applications, 11, 133. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Saleem, F. (2017). Dapagliflozin: cardiovascular safety and benefits in type 2 diabetes mellitus. Cureus, 9(10). |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Palanisamy, S., Yien, E. L. H., Shi, L. W., Si, L. Y., Qi, S. H., Ling, L. S. C., ... & Chen, Y. N. (2018). Systematic review of efficacy and safety of newer antidiabetic drugs approved from 2013 to 2017 in controlling HbA1c in diabetes patients. Pharmacy, 6(3), 57. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Li, F. F., Liu, B. L., Yan, R. N., Zhu, H. H., Zhou, P. H., Li, H. Q., ... & Ma, J. H. (2017). Features of glycemic variations in drug naïve type 2 diabetic patients with different HbA 1c values. Scientific reports, 7(1), 1-7. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Chehregosha, H., Khamseh, M. E., Malek, M., Hosseinpanah, F., & Ismail-Beigi, F. (2019). A view beyond HbA1c: role of continuous glucose monitoring. Diabetes Therapy, 10(3), 853-863. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Luc, K., Schramm-Luc, A., Guzik, T. J., & Mikolajczyk, T. P. (2019). Oxidative stress and inflammatory markers in prediabetes and diabetes. J. Physiol. Pharmacol, 70(6), 809-824. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
RÃ¥dholm, K., Wu, J. H., Wong, M. G., Foote, C., Fulcher, G., Mahaffey, K. W., ... & Neal, B. (2018). Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetesâA systematic review. diabetes research and clinical practice, 140, 118-128. |
| View at Publisher | View at Google Scholar | View at Indexing | |
|
Hayashi, T., Fukui, T., Nakanishi, N., Yamamoto, S., Tomoyasu, M., Osamura, A., ... & Hirano, T. (2017). Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovascular diabetology, 16(1), 1-13. |
| View at Publisher | View at Google Scholar | View at Indexing | |
